PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pfizer and Anumana boost detection of cardiovascular disease

The partnership will support the development of a new algorithm and identify at-risk patients.

Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.

Based on a multi-year agreement, Anumana will embark on a clinical validation trial, while pursuing De Novo classification for the algorithm as a ‘Software-as-a-Medical-Device’ (SaMD). It also aims to gain regulatory approval for the detection of cardiac amyloidosis across Europe, the US and Japan.

The research partnership will support Anumana’s efforts to implement AI-enabled early detection software. Critically, the technology reveals signals from ECGs that humans cannot usually interpret. Furthermore, the nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier.

David McMullin, a chief business officer at Anumana, reflected: “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress.”

He added: “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.”

Paul Friedman, chair of Anumana’s Mayo Clinic board of advisors, concluded: “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease.”

He added: “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.”

Cardiac amyloidosis is a serious, progressive and underdiagnosed rare disease that leads to heart failure. In patients with the condition, heart walls become stiff, making it difficult for the left ventricle to relax and fill with blood, hampering its ability to squeeze and pump blood out of the heart.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026